• Steven M Greenberg, Rustam Al-Shahi Salman, Geert Jan Biessels, Mark van Buchem, Charlotte Cordonnier, Jin-Moo Lee, Joan Montaner, Julie A Schneider, Eric E Smith, Meike Vernooij, and David J Werring.
• Stroke Research Center, Massachusetts General Hospital, Boston, MA, USA. Electronic address: sgreenberg@partners.org.
• Lancet Neurol. 2014 Apr 1; 13 (4): 419428419-28.

AbstractEfforts are underway for early-phase trials of candidate treatments for cerebral amyloid angiopathy, an untreatable cause of haemorrhagic stroke and vascular cognitive impairment. A major barrier to these trials is the absence of consensus on measurement of treatment effectiveness. A range of potential outcome markers for cerebral amyloid angiopathy can be measured against the ideal criteria of being clinically meaningful, closely representative of biological progression, efficient for small or short trials, reliably measurable, and cost effective. In practice, outcomes tend either to have high clinical salience but low statistical efficiency, and thus more applicability for late-phase studies, or greater statistical efficiency but more limited clinical meaning. The most statistically efficient markers might be those that are potentially reversible with treatment, although their clinical significance remains unproven. Many of the candidate outcomes for cerebral amyloid angiopathy trials are probably applicable also to other small-vessel brain diseases.Copyright © 2014 Elsevier Ltd. All rights reserved.

7 keywords...

hide…